Drugs Made In America Acquisition Corp.
DMAAU- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0002028614
No open-market purchases or sales by Drugs Made In America Acquisition Corp. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $122.3K in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Drugs Made In America Acquisition Corp. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +15 vs. Q4 2024
- Shares held
- 3.29M
- +3.29M vs. Q4 2024
- Total value
- $33.4M
- +$33.4M vs. Q4 2024
- New holders
- 15
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMAAU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $122.3K |
| Q1 2026 | 2 | $121.0K |
| Q4 2025 | 5 | $5.77M |
| Q3 2025 | 8 | $6.73M |
| Q2 2025 | 9 | $10.2M |
| Q1 2025 | 15 | $33.4M |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Drugs Made In America Acquisition Corp.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Heights Capital Management, Inc | 650,000 | $6.58M | 3.15% | +650,000 | New |
| Boothbay Fund Management, LLC | 603,750 | $6.14M | 0.22% | +603,750 | New |
| Westchester Capital Management, LLC | 500,000 | $5.06M | 0.29% | +500,000 | New |
| Rivernorth Capital Management, LLC | 420,498 | $4.28M | 0.23% | +420,498 | New |
| Context Capital Management, LLC | 250,000 | $2.54M | 0.10% | +250,000 | New |
| Schonfeld Strategic Advisors LLC | 234,831 | $2.39M | 0.02% | +234,831 | New |
| Bulldog Investors, LLP | 130,264 | $1.32M | 0.36% | +130,264 | New |
| Wolverine Asset Management LLC | 130,000 | $1.32M | 0.03% | +130,000 | New |
| Parallax Volatility Advisers, L.P. | 100,000 | $1.02M | 0.03% | +100,000 | New |
| Verition Fund Management LLC | 100,000 | $1.01M | 0.01% | +100,000 | New |
| Murchinson Ltd. | 90,000 | $915.3K | 0.16% | +90,000 | New |
| Tuttle Tactical Management | 40,000 | $406.8K | 1.79% | +40,000 | New |
| UBS Group AG | 18,278 | $185.9K | 0.00% | +18,278 | New |
| Citadel Advisors LLC | 15,753 | $159.4K | 0.00% | +15,753 | New |
| Clear Street LLC | 5,849 | $59.5K | 0.00% | +5,849 | New |